Our Strategy
PediatRx, Inc., (PEDX.OB), is a specialty pharmaceutical company that brings prescription,
branded pharmaceuticals to healthcare professionals for the treatment of serious
medical conditions that require hospitalization, or to be treated under the care
of hospital specialists. The company has an initial focus on oncology supportive
care.
We believe that our singular focus on the acquisition, development, and commercialization
of pharmaceutical drugs approved by the United States Food and Drug Administration,
ultimately for use in special oncology populations and supportive care is a competitive
advantage over otherwise similar pharmaceutical companies.
We differ from many early stage pharmaceutical companies in that we intend to devote
a large portion of our efforts and capital to licensing/acquisition, and to commercialization
efforts.
Many early stage pharmaceutical companies devote a greater portion of their capital
to research and development with no expectation of revenue from product sales in
the foreseeable future.
We intend to develop our business by acquiring rights to, and/or substantially all
of the assets associated with drugs already approved for use in categories of interest
and to become the sole distributor of such products in the United States.
We intend to accelerate our recovery of acquisition costs and to add value through
four principal means:
- Marketing
- Reformulation
- Extension into adjacent fields
- Expanded distribution through partnerships
The pharmaceutical industry is undergoing dramatic change. Large companies have
dry pipelines, despite massive investment in research and development. Still, many
companies tend to be inwardly focused and squander countless hours, resources and
opportunities. They are shedding tens of thousands of employees and divesting non-core
assets. Investors are demanding greater returns and turning to more exciting investments
and pharmaceutical companies with novel strategies.
The PediatRx model is set to capitalize on opportunities born out of these changes.
Innovation does not now necessarily mean creating novel drugs which have never before
existed, though clearly that is still the life blood of pharmaceutical research
and development. PediatRx is innovating the way it has started and operates a pharmaceutical
company. Some of what we do depends on outsourced partners who can do that one particular
thing we may need with laser-like focus, leading to efficiency and effectiveness.
We are innovating by focusing our business in areas so far unexplored by other companies,
large or small.
We have a unique culture, that we believe will continue to attract the best and
brightest talent. And we are relentlessly focused on patients, healthcare professionals
and other stakeholders on the receiving end of our products. We do not incur costly
infrastructure nor take on the burden of discovery or drug research and development.
Rather, we find existing products that have been ignored or under-promoted that
have real benefit. In most cases, the opportunity is not obvious to others. But
with vision, creativity and belief in the benefit those products may bring the practice
of medicine, we apply focused resource to bringing those products to market. We
acknowledge that there are many therapeutics that aren’t realizing their full potential.
However, by managing them more efficiently and more strategically through their
lifecycle and looking for uses and customer segments ignored by larger companies,
as well as using smart, cost-effective methods to engage customers, we are able
to bring unexploited value.
We believe these operating principles also make us an ideal partner and it's through
this approach to providing creative and cost-efficient value that we will deliver
long-term growth, profitability and trust.